These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 19525224

  • 1. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
    Maxwell SA, Li Z, Jaya D, Ballard S, Ferrell J, Fu H.
    J Biol Chem; 2009 Aug 14; 284(33):22379-22389. PubMed ID: 19525224
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
    Wang S, Sun L.
    Bioengineered; 2021 Dec 14; 12(1):8296-8308. PubMed ID: 34565287
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N, Wang CY, Sun YQ, Ruan YJ, Huang YY, Su T, Zhou XH, Huang H, Guo WJ, He MQ, Yao RX, Lin XJ.
    Biomed Pharmacother; 2018 Oct 14; 106():267-274. PubMed ID: 29966970
    [Abstract] [Full Text] [Related]

  • 7. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.
    Song YH, Zhong MZ, Gan PP, Yi PY, Tang YH, Liu YP, Jiang JQ, Li L.
    Tumour Biol; 2014 Dec 14; 35(12):11809-17. PubMed ID: 25344211
    [Abstract] [Full Text] [Related]

  • 8. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
    Chen J, Ge X, Zhang W, Ding P, Du Y, Wang Q, Li L, Fang L, Sun Y, Zhang P, Zhou Y, Zhang L, Lv X, Li L, Zhang X, Zhang Q, Xue K, Gu H, Lei Q, Wong J, Hu W.
    Theranostics; 2020 Dec 14; 10(7):3151-3163. PubMed ID: 32194860
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
    Araie H, Sakamaki I, Matsuda Y, Tai K, Ikegaya S, Itoh K, Kishi S, Oiwa K, Okura M, Tasaki T, Hosono N, Ueda T, Yamauchi T.
    Intern Med; 2017 Sep 15; 56(18):2407-2413. PubMed ID: 28824057
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients.
    Park LC, Song YJ, Kim DJ, Kim MJ, Jo JC, Lee WS, Shin HJ, Oh SY, Do YR, Jeong JY, Lee HS, Consortium for Improving Survival of Lymphoma (CISL).
    Int J Cancer; 2019 Nov 01; 145(9):2459-2467. PubMed ID: 30973963
    [Abstract] [Full Text] [Related]

  • 14. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
    Knight C, Hind D, Brewer N, Abbott V.
    Health Technol Assess; 2004 Sep 01; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
    [Abstract] [Full Text] [Related]

  • 15. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.
    J Egypt Natl Canc Inst; 2011 Mar 01; 23(1):17-24. PubMed ID: 22099932
    [Abstract] [Full Text] [Related]

  • 16. Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP.
    Song G, Song G, Ni H, Gu L, Liu H, Chen B, He B, Pan Y, Wang S, Cho WC.
    Curr Cancer Drug Targets; 2014 Mar 01; 14(7):659-70. PubMed ID: 25146331
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y, Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Bi X, Sun P, Huang HQ, Lin TY, Guan ZZ, Li ZM.
    Ann Hematol; 2015 Nov 01; 94(11):1865-73. PubMed ID: 26327569
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F, Ravasio R.
    Clin Drug Investig; 2008 Nov 01; 28(1):55-65. PubMed ID: 18081361
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.